The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries
Open accessAbstract
Objectives: To assess the effects of costs on access to medicines in 11 developed countries offering different levels of prescription drug coverage for their populations. Design: Cross-sectional study of data from the Commonwealth Fund 2014 International Health Policy Survey of Older Adults. Setting: Telephone survey conducted in 11 high-income countries: Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the UK and the USA. Participants: 22 532 adults aged 55 and older and living in the community in studied countries. Primary outcome measure: Self-reported cost-related non-adherence (CRNA) in the form of either not filling a prescription or skipping doses within the last 12 months because of out-of-pocket costs. Results: Estimated prevalence of CRNA among all older adults varied from <3% in the France, Norway, Sweden, Switzerland and the UK to 16.8% in the USA. Canada had the second highest national prevalence of CRNA (8.3%), followed by Australia (6.8%). Older adults in the USA were approximately six times more likely to report CRNA than older adults in the UK (adjusted OR=6.09; 95% CI 3.60 to 10.20). Older adults in Australia and Canada were also statistically significantly more likely to report CRNA than older adults in the UK. Across most countries, the prevalence of CRNA was higher among lower income residents and lower among residents over age 65. Conclusions: Observed differences in national prevalence of CRNA appear to follow lines of availability of prescription drug coverage and the extent of direct patient charges for prescriptions under available drug plans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well established that high prices are barriers to access to medications, particularly for AOMs [12].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revisiting the Behavioral Model and Access to Medical Care: Does it Matter?
Andersen, R. M. (1995) · Journal of Health and Social Behavior · doi:10.2307/2137284 · Cited by 9,831
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169
Factors affecting therapeutic compliance: A review from the patient’s perspective
Li, S.-C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1458 · Cited by 1,290
Prescription Drug Cost Sharing
Goldman, D. P., Joyce, G., & Zheng, Y. (2007) · JAMA · doi:10.1001/jama.298.1.61 · Cited by 890
Patients At-Risk for Cost-Related Medication Nonadherence: A Review of the Literature
Briesacher, B. A., Gurwitz, J. H., & Soumerai, S. B. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0180-x · Cited by 389
The effect of cost on adherence to prescription medications in Canada
Law, M. R., Cheng, L., Dhalla, I. A., Heard, D., & Morgan, S. G. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.111270 · Cited by 232
Self-citationOsborn, R., Moulds, D., Squires, D. A., Doty, M. M., & Anderson, C. (2014) · Health Affairs · doi:10.1377/hlthaff.2014.0947 · Cited by 212
Pharmaceutical policies: effects of cap and co-payment on rational drug use
Austvoll‐Dahlgren, A., Aaserud, M., Vist, G. E., Ramsay, C. R., Oxman, A. D., Sturm, H., Kösters, J. P., & Vernby, Å. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007017 · Cited by 166
Prescription Drug Insurance Coverage and Patient Health Outcomes: A Systematic Review
Kesselheim, A. S., Huybrechts, K. F., Choudhry, N. K., Fulchino, L. A., Isaman, D. L., Kowal, M. K., & Brennan, T. A. (2014) · American Journal of Public Health · doi:10.2105/ajph.2014.302240 · Cited by 83
Kennedy, J. J., & Morgan, S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.009 · Cited by 71
Self-citation
Cited by
Sorted by citations
Medications safety pharmacoeconomics-related issues
Al‐Worafi, Y. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819837-7.00016-9 · Cited by 367
Sendekie, A. K., Netere, A. K., Kasahun, A. E., & Belachew, E. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274971 · Cited by 127
The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey
Law, M. R., Cheng, L., Kolhatkar, A., Goldsmith, L. J., Morgan, S. G., Holbrook, A. M., & Dhalla, I. A. (2018) · CMAJ Open · doi:10.9778/cmajo.20180008 · Cited by 88
Self-citationBhattarai, B., Walpola, R. L., Mey, A., Anoopkumar‐Dukie, S., & Khan, S. A. (2020) · Respiratory Care · doi:10.4187/respcare.07355 · Cited by 79
Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69
“It is well established that high prices are barriers to access to medications, particularly for AOMs [12].”
BackgroundDefining the concept of fair pricing for medicines
Moon, S., Mariat, S., Kamae, I., & Pedersen, H. B. (2020) · BMJ · doi:10.1136/bmj.l4726 · Cited by 65
Jansen, C., Baker, J. D., Kodaira, E., Ang, L., Bacani, A. J., Aldan, J. T., Shimoda, L. M. N., Salameh, M. I., Small-Howard, A. L., Stokes, A. J., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113477 · Cited by 63
Goldsmith, L. J., Kolhatkar, A., Popowich, D., Holbrook, A. M., Morgan, S. G., & Law, M. R. (2017) · Social Science & Medicine · doi:10.1016/j.socscimed.2017.10.007 · Cited by 48
Self-citationMancia, G., Cappuccio, F. P., Burnier, M., Coca, A., Persu, A., Borghi, C., Kreutz, R. H., & Sanner, B. M. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13678 · Cited by 55
Holbrook, A. M., Wang, M., Lee, M., Chen, Z., Garcia, M. C., Nguyen, L. N., Ford, A., Manji, S., & Law, M. R. (2021) · Systematic Reviews · doi:10.1186/s13643-020-01558-5 · Cited by 45
Weir, D. L., Motulsky, A., Abrahamowicz, M., Lee, T. C., Morgan, S. G., Buckeridge, D. L., & Tamblyn, R. M. (2020) · Health Services Research · doi:10.1111/1475-6773.13292 · Cited by 38
Self-citationManagement of endometriosis: Toward value-based, cost-effective, affordable care
Vercellini, P., Facchin, F., Buggio, L., Barbara, G., Berlanda, N., Frattaruolo, M. P., & Somigliana, E. (2018) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2017.07.011 · Cited by 36
Roser, P., Bajaj, S. S., & Stanford, F. C. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01176-2 · Cited by 34
Zhou, T., Liu, P., Dhruva, S. S., Shah, N. D., Ramachandran, R., Berg, K. M., & Ross, J. S. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7457 · Cited by 35
Ihm, S., Kim, K., Lee, K. J., Won, J. W., Na, J. O., Rha, S., Kim, H., Kim, S., & Shin, J. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0226 · Cited by 36
Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
Hajizadeh, M., & Edmonds, S. (2019) · International Journal of Health Policy and Management · doi:10.15171/ijhpm.2019.93 · Cited by 33
Medication adherence: understanding the issues and finding solutions
While, A. (2020) · British Journal of Community Nursing · doi:10.12968/bjcn.2020.25.10.474 · Cited by 30
Age and gender differences in financial distress among hematopoietic cell transplant survivors
Jones, S. M. W., Yi, J. C., Jim, H., Loren, A. W., Majhail, N. S., Uberti, J. P., Whalen, V., Leisenring, W. M., Flowers, M. E. D., Lee, S. J., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-019-05291-1 · Cited by 29
Kassaw, A. T., Sendekie, A. K., Minyihun, A., & Gebresillassie, B. M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1369569 · Cited by 42
Minhas, D., Marder, W., Harlow, S. D., Hassett, A. L., Zick, S. M., Gordon, C., Barbour, K. E., Helmick, C. G., Wang, L., Lee, J., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24397 · Cited by 28
Healing an ailing pharmaceutical system: prescription for reform for United States and Canada
Gaffney, A. W., Lexchin, J., US, & Canadian Pharmaceutical Policy Reform Working Group (2018) · BMJ · doi:10.1136/bmj.k1039 · Cited by 30
Edmonds, S., & Hajizadeh, M. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01074-x · Cited by 24
Evaluating the effects of Quebec’s private–public drug insurance system
Morgan, S. G., Gagnon, M., Charbonneau, M., & Vadeboncœur, A. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170726 · Cited by 23
Self-citationPersaud, N., Bedard, M. J., Boozary, A., Glazier, R. H., Gomes, T., Hwang, S. W., Jüni, P., Law, M. R., Mamdani, M., Manns, B., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003590 · Cited by 21
Self-citationCost variation analysis of oral anti-diabetic drugs
Mehani, R., & Sharma, P. (2018) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20183476 · Cited by 21
Bekele, B. B., Alhaffar, M. B. A., Wasnik, R. N., & Sándor, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042258 · Cited by 19
Jeyalakshmi, K., Rao, M., Shashidhara, Y. N., Thunga, G., Ravishankar, N., Sudhakar, C., & Devi, E. S. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s380784 · Cited by 21
Cost-related medication underuse: Strategies to improve medication adherence at care transitions
Miranda, A. C., Serag-Bolos, E. S., & Cooper, J. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz010 · Cited by 19
Magrey, M., Walsh, J. A., Flierl, S., Howard, R. A., Calheiros, R. C., Wei, D., & Khan, M. A. (2023) · ACR Open Rheumatology · doi:10.1002/acr2.11543 · Cited by 18
Addressing Medication Costs During Primary Care Visits: A Before–After Study of Team-Based Training
Carroll, J. K., Farah, S., Fortuna, R. J., Lanigan, A. M., Sanders, M., Venci, J. V., & Fiscella, K. A. (2019) · Annals of Internal Medicine · doi:10.7326/m18-2011 · Cited by 19
Lexchin, J. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.4753 · Cited by 18
Yong, P. J., Alsowayan, N., Noga, H. L., Williams, C., Allaire, C., Lisonkova, S., & Bedaiwy, M. A. (2020) · Human Reproduction Open · doi:10.1093/hropen/hoz040 · Cited by 17
Cross-sectional analysis of factors associated with medication adherence in western Kenya
Gala, P., Kamano, J. H., Sanchez, M. V., Mugo, R., Orango, V., Pastakia, S. D., Horowitz, C. R., Hogan, J. W., & Vedanthan, R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072358 · Cited by 15
Charbonneau, M., & Gagnon, M. (2018) · Health Policy · doi:10.1016/j.healthpol.2018.08.006 · Cited by 15
Schönfeld, S., Denhaerynck, K., Berben, L., Dobbels, F., Russell, C. L., Crespo-Leiro, M. G., Geest, S. D., & On behalf of the BRIGHT Study Team† (2020) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000683 · Cited by 15
Fenta, E. T., Ayal, B. G., Kidie, A. A., Anagaw, T. F., Mekonnen, T., Bogale, E. K., Berihun, S., Tsega, T. D., Munie, C. M., Fenta, T. T., et al. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s452196 · Cited by 21
Cost-related nonadherence for prescription medications: a cross-sectional study in Jordan
Naser, A. Y. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1899814 · Cited by 13
Jx, Z., Bhaumik, D., Huang, E. S., & Meltzer, D. O. (2019) · doi:10.36648/2471-9927.4.2.40 · Cited by 19
O’Hara, D. V., Janse, R. J., Fu, E. L., Jardine, M., & Carrero, J. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111745 · Cited by 13
Patient Compliance: Fact or Fiction?
Mohiuddin, A. K. (2019) · INNOVATIONS in pharmacy · doi:10.24926/iip.v10i1.1621 · Cited by 14
RetractedRättö, H., & Aaltonen, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250305 · Cited by 16
Zhang, J., Bhaumik, D., & Meltzer, D. O. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051480 · Cited by 12
Campbell, A., Coley, K. C., Corbo, J. M., DeLellis, T., Joseph, M., Thorpe, C. T., McGivney, M. S., Klatt, P. M., Cox-Vance, L., Balestrino, V., et al. (2018) · Europe PMC (PubMed Central) · Cited by 12
Soril, L. J. J., Adams, T., Phipps-Taylor, M., Winblad, U., & Clement, F. M. (2017) · Healthcare policy · doi:10.12927/hcpol.2017.25192 · Cited by 12
Hedenrud, T., Jakobsson, A., Malla, H. E., & Håkonsen, H. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0934-3 · Cited by 9
Larkin, J., Foley, L., Timmons, S., Hickey, T., Clyne, B., Harrington, P., & Smith, S. M. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02738-9 · Cited by 12
Universal drug coverage and income‐related disparities in glycaemic control
Day, L. B., Austin, P. C., & Shah, B. R. (2019) · Diabetic Medicine · doi:10.1111/dme.14051 · Cited by 10
Warth, J., Puth, M., Tillmann, J., Beckmann, N., Porz, J., Zier, U., Weckbecker, K., Weltermann, B., & Münster, E. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4710-0 · Cited by 10
Laba, T., Cheng, L., Worthington, H. C., McGrail, K. M., Chan, F. K. I., Mamdani, M., & Law, M. R. (2020) · Health Policy · doi:10.1016/j.healthpol.2020.05.001 · Cited by 10
Wawruch, M., Murín, J., Tesař, T., Padúchová, M., Petrová, M., Čelovská, D., Matalová, P., Havelkova, B., Trnka, M., & Aarnio, E. (2021) · Biomedicines · doi:10.3390/biomedicines9121800 · Cited by 10
Rationalizing Pharmaceutical Spending
García‐Goñi, M. (2022) · IMF Working Paper · doi:10.5089/9798400219849.001 · Cited by 10
The rising cost of rhinologic medications
Vasudev, M., Torabi, S. J., Michelle, L., Meller, L. L. T., Birkenbeuel, J. L., Roman, K. M., Nguyen, T. V., & Kuan, E. C. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.04.013 · Cited by 9
Minhas, D., Marder, W., Hassett, A. L., Zick, S. M., Gordon, C., Harlow, S. D., Wang, L., Barbour, K. E., Helmick, C. G., McCune, W. J., et al. (2023) · Lupus · doi:10.1177/09612033231186113 · Cited by 8
Warth, J., Puth, M., Zier, U., Beckmann, N., Porz, J., Tillmann, J., Weckbecker, K., Bosma, H., Weltermann, B., & Münster, E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232716 · Cited by 7
Evaluation of the Post-Training Hypotensor Effect in Paralympic and Conventional Powerlifting
Aidar, F. J., Paz, Â. D. A., de Matos, D. G., de Souza, R. F., Souza, L. M. V., dos Santos, J. L., de Almeida‐Neto, P. F., Marçal, A. C., Neves, E. B., Moreira, O. C., et al. (2021) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk6040092 · Cited by 7
Zheng, C., & Chagpar, A. B. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06510-w · Cited by 8
Adams, K., Garg, S., Tartof, S. Y., Irving, S. A., DeSilva, M. B., Klein, N. P., Natarajan, K., Dascomb, K. K., Grannis, S. J., Ong, T. C., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf178 · Cited by 6
Variation of prescription drug prices in community pharmacies: A national cross-sectional study
Larkin, J., Moriarty, F., McGuinness, S., Finucane, K., Fitzgerald, K. R., Smith, S. M., & O’Mahony, J. F. (2022) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2022.05.007 · Cited by 6
The impact of prescription drug co-payments for publicly insured families
Mohan, G., & Nolan, A. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01125-3 · Cited by 6
The Benefits and Risks of Adherence to Medical Therapy
Scialli, A., Saavedra, K., & Fugh-Berman, A. (2021) · The Journal of Scientific Practice and Integrity · doi:10.35122/001c.21386 · Cited by 4
Liquidity Constraints and Demand for Healthcare: Evidence from Danish Welfare RecipientsPreprint
Lyngse, F. P. (2020) · RePEc: Research Papers in Economics · doi:10.48550/arxiv.2010.14651 · Cited by 7
Berger, T., Zeitlinger, M. A., Popescu, V., Magyari, M., Airas, L. M., Alkhawajah, M. M., Pugliatti, M., Zakaria, M. F., Pozzilli, C., Drulovic, J. S., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70140 · Cited by 5
Cost-related nonadherence with glaucoma medications in Ontario
Buys, Y. M., Kagan, D. B., Jin, Y.-P., & Trope, G. E. (2021) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2021.01.008 · Cited by 5
Roshi, D., Burazeri, G., Italia, S., Schröder‐Bäck, P., Ylli, A., & Brand, H. (2021) · Eastern Mediterranean Health Journal · doi:10.26719/emhj.21.008 · Cited by 5
Bhattarai, B., Walpola, R. L., Khan, S. A., & Mey, A. (2021) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2021.100049 · Cited by 5
Cost-related nonadherence can be explained by a general nonadherence framework
Alefan, Q., Cheekireddy, M., & Blackburn, D. F. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.01.011 · Cited by 5
Daw, J. R., & Law, M. R. (2020) · Health Affairs · doi:10.1377/hlthaff.2019.01554 · Cited by 5
Predicting patent challenges for small-molecule drugs: A cross-sectional study
Memedovich, A., Steele, B. J., Orr, T., Chaudhry, S., Tadrous, M., Kesselheim, A. S., Hollis, A., & Beall, R. F. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004540 · Cited by 4
Larkin, J., Smith, S. M., Christensen, L. D., Voss, T., Vestergaard, C., Paust, A., & Prior, A. (2023) · medRxiv · doi:10.1016/j.sapharm.2025.03.009 · Cited by 4
Strategies to Reduce Out-of-Pocket Medication Costs for Canadians Living with Heart Failure
McIntyre, W. F., Belesiotis, P., McClure, G. R., Demers, C., Chahil, G., Hayes, A., Sohi, G. K., Bordman, W., Whitlock, R. P., & Belley‐Côté, E. P. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07046-1 · Cited by 4
Bishop, M. A., Chang, H., Kitchen, C., Weiner, J. P., Kharrazi, H. H. K., & Shermock, K. M. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.8.1009 · Cited by 4
Rarani, M. A., Karimi, S., & Gharacheh, L. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08953-9 · Cited by 4
Amoud, R., Grindrod, K., Cooke, M. J., & Alsabbagh, M. W. (2020) · Healthcare policy · doi:10.12927/hcpol.2020.26351 · Cited by 3
ORAL ANTIDIABETICS AGENTS AVAILABLE IN INDIAN PHARMACEUTICAL MARKET: A PRICE VARIATION ANALYSIS
Thacker, K. S., Mistry, V. R., & Kanani, N. J. (2020) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2020.v13i3.36498 · Cited by 3
Torabipour, A., Karimi, S., Rarani, M. A., & Gharacheh, L. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12222-w · Cited by 4
Drug prices: How do we get to a better place?
Lexchin, J. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170440 · Cited by 3
Jackevicius, C. A., & Ko, D. T. (2019) · JAMA · doi:10.1001/jama.2018.20396 · Cited by 3
Uribe-Rodríguez, A. F., Rivero, P. F. P., Free, C., Perel, P., Murray, E., Díaz, N. S., Horne, R., Atkins, L., Casas, J. P., & Bermon, A. (2019) · medRxiv · doi:10.1101/19002683 · Cited by 3
Medication adherence: understanding the issues and finding solutions
While, A. (2020) · Journal of Prescribing Practice · doi:10.12968/jprp.2020.2.11.598 · Cited by 2
Facilitators and barriers of medication adherence amongst the geriatrics: a cross-sectional study
Dharvees, T. M., Crasta, D. S., Stephen, S. M., Thomas, A., Pereira, P., Ramesh, M., Chalasani, S. H., & Syed, J. M. (2022) · Journal of Pharmaceutical Health Services Research · doi:10.1093/jphsr/rmac023 · Cited by 2
Larkin, J., Prendergast, C., Murry, L., Flood, M., Clyne, B., Burke, S., Keegan, C., Boland, F., Fahey, T., Persaud, N., et al. (2024) · medRxiv · doi:10.1016/j.rcsop.2025.100565 · Cited by 2
Cost-related nonadherence to medications and pharmacare.
Doucet, J. (2017) · PubMed Central · Cited by 2
Mood, cognitive structuring and medication adherence
Doliński, D., Dolińska, B., & Bar‐Tal, Y. (2018) · Health Care For Women International · doi:10.1080/07399332.2018.1458852 · Cited by 2
OHIP Plus or Minus? An Examination of OHIP+ and its Implications for Universal Pharmacare in Canada
Pullen, N. (2019) · Carleton Perspectives on Public Policy · doi:10.22215/cpopp.v5i0.1380 · Cited by 2
Cost variation analysis of oral anti-diabetic agents available in Indian market
Gedam, S., & Barmaiya, N. (2021) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20212080 · Cited by 2
Ethische Sichtweise auf hochpreisige Arzneimittel
Nagel, E., Henzler, D., & Lauerer, M. (2021) · Springer eBooks · doi:10.1007/978-3-662-63929-0_4 · Cited by 3
Unfortunate distinction or corporate protectionism by design?
Chaufan, C., & Mohamed, F. A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30160-4 · Cited by 2
Chugh, P. K., Gupta, P., Wasan, H., Tripathi, C. D., Chandy, S. J., Ranjalkar, J., Bright, H. R., Badyal, D. K., Samuel, M. P., Jhaj, R., et al. (2024) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_61_23 · Cited by 1
Passi, R., Kaur, M., Gupta, M., Kumari, S., & Kumar, R. (2025) · SAGE Open · doi:10.1177/21582440251339053 · Cited by 1
Ansong, R., Kyei, G. K., Miezah, D., Abubakari, M., & Kyei, E. F. (2026) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-026-02863-w · Cited by 1
Myths and Realities About Why Prescription Drug Prices in the United States Are So High
Lexchin, J. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0191-9 · Cited by 1
Pre-stroke Adherence to Hypertension Medications in a Bi-racial United States Stroke Belt
Bruno, A., Muppa, J., & Cabahug, I. N. K. V. (2023) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-023-00581-6 · Cited by 1
Gender and racialisation of pharmaceutical sector leaders in Canada: a cross-sectional study
Satgunanathan, K., Workentin, A., Woods, H., Sabir, A., & Persaud, N. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076235 · Cited by 1
Artignan, J., Capmas, P., Panjo, H., Constantinou, P., & Pelletier‐Fleury, N. (2023) · BMC Medicine · doi:10.1186/s12916-023-03156-3 · Cited by 2
Pharmacare and Access to Medicines
Gagnon, M. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197766859.013.0029 · Cited by 1
Chevalier, B. A. M. (2017) · The University of Queensland · doi:10.14264/uql.2017.993 · Cited by 1
Larkin, J., Foley, L., Timmons, S., Hickey, T., Clyne, B., Harrington, P., & Smith, S. M. (2023) · medRxiv · doi:10.1101/2023.04.10.23288383 · Cited by 1
Doucet, J. (2017) · PubMed Central
Krůtilová, V., & Doubková, D. (2021) · Kontakt · doi:10.32725/kont.2021.020
Metadata
- Authors
- Morgan, S. G., & Lee, A.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Morgan, Steven G
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-01
- Volume
- 7
- Issue
- 1
- Pages
- e014287
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5293866
- OpenAlex
- W2583329548
- Cited by
- 112
- References
- 16
- Citations by year
- 2026: 1 · 2025: 12 · 2024: 5 · 2023: 16 · 2022: 12 · 2021: 17 · 2020: 20 · 2019: 13 · 2018: 7 · 2017: 9
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Commonwealth Fund (20160646)
- Institute of Gender and Health (DCO150GP)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- cost-related nonadherence, medication adherence, older adults, prescription drug coverage, out-of-pocket costs, access to medicines, income inequality, cross-national comparison
- MeSH terms
- Assessment of Medication Adherence, Aged, Australia, Canada, Cross-Sectional Studies, Europe, Health Expenditures, Female, Humans, Income, Insurance, Pharmaceutical Services, Male, Middle Aged, New Zealand, Surveys and Questionnaires, United States, Drug Monitoring, Cost of Illness, Developed Countries, Insurance Coverage, Universal Health Insurance, Medication Adherence, Prescription Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
